Conditions: Breast Cancer
Keywords: Breast Cancer ER-negative Allred Score
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 4
Healthy volunteers: no

Brief summary:
If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be possible to effectively use hormonal therapy in these patients resulting in improved outcomes. The investigators propose a single-arm Simon two-step study to examine whether treatment with AZD6244 will result in increased ER expression in ER-negative/low primary breast tumors.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: AZ6244
Intervention descriptions: intervention 1: AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15

Protocol document: